Literature DB >> 8469325

T2 relaxation time in patients with Parkinson's disease.

A Antonini1, K L Leenders, D Meier, W H Oertel, P Boesiger, M Anliker.   

Abstract

Postmortem studies of patients with Parkinson's disease (PD) reveal an increase in iron concentration in the substantia nigra. Iron content in the brain is associated with decreased signal intensity on T2-weighted MRI. We measured in vivo the T2 relaxation time in 30 PD patients and 33 healthy volunteer subjects, using a 1.5-T whole-body MRI system. In comparison with healthy controls, T2 values in PD patients were reduced in the following brain regions: substantia nigra, caudate nucleus, and putamen. Due to the overlap between patients and control subjects, we could not differentiate, in a given patient, healthy from diseased state on the basis of T2 relaxation time. Our findings support the notion of increased iron deposition in the substantia nigra of patients with PD. However, the shortening of T2 values in the substantia nigra did not correlate with disease duration nor with clinical severity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469325     DOI: 10.1212/wnl.43.4.697

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings.

Authors:  Hirobumi Oikawa; Makoto Sasaki; Yoshiharu Tamakawa; Shigeru Ehara; Koujiro Tohyama
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

2.  Toward understanding transverse relaxation in human brain through its field dependence.

Authors:  Fumiyuki Mitsumori; Hidehiro Watanabe; Nobuhiro Takaya; Michael Garwood; Edward J Auerbach; Shalom Michaeli; Silvia Mangia
Journal:  Magn Reson Med       Date:  2011-12-08       Impact factor: 4.668

3.  Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.

Authors:  Y Murakami; S Kakeda; K Watanabe; I Ueda; A Ogasawara; J Moriya; S Ide; K Futatsuya; T Sato; K Okada; T Uozumi; S Tsuji; T Liu; Y Wang; Y Korogi
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

4.  Age-related differences in iron content of subcortical nuclei observed in vivo: a meta-analysis.

Authors:  Ana Daugherty; Naftali Raz
Journal:  Neuroimage       Date:  2012-12-28       Impact factor: 6.556

Review 5.  Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.

Authors:  Adriane Gröger; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2012-08-09       Impact factor: 3.575

Review 6.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

Review 7.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

8.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

9.  Progressive supranuclear palsy: high-field-strength MR microscopy in the human substantia nigra and globus pallidus.

Authors:  Parastou Foroutan; Melissa E Murray; Shinsuke Fujioka; Katherine J Schweitzer; Dennis W Dickson; Zbigniew K Wszolek; Samuel C Grant
Journal:  Radiology       Date:  2012-11-14       Impact factor: 11.105

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.